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Abstract
Background: Escherichia coli is the commonest cause of community and nosocomial urinary tract
infection (UTI). Antibiotic treatment is usually empirical relying on susceptibility data from local
surveillance studies. We therefore set out to determine levels of resistance to 8 commonly used
antimicrobial agents amongst all urinary isolates obtained over a 12 month period.
Methods: Antimicrobial susceptibility to ampicillin, amoxicillin/clavulanate, cefalexin, ciprofloxacin,
gentamicin, nitrofurantoin, trimethoprim and cefpodoxime was determined for 11,865 E. coli
urinary isolates obtained from community and hospitalised patients in East London.
Results: Nitrofurantoin was the most active agent (94% susceptible), followed by gentamicin and
cefpodoxime. High rates of resistance to ampicillin (55%) and trimethoprim (40%), often in
combination were observed in both sets of isolates. Although isolates exhibiting resistance to
multiple drug classes were rare, resistance to cefpodoxime, indicative of Extended spectrum β-
lactamase production, was observed in 5.7% of community and 21.6% of nosocomial isolates.
Conclusion: With the exception of nitrofurantoin, resistance to agents commonly used as
empirical oral treatments for UTI was extremely high. Levels of resistance to trimethoprim and
ampicillin render them unsuitable for empirical use. Continued surveillance and investigation of
other oral agents for treatment of UTI in the community is required.
Background
Escherichia coli is the predominant cause of both commu-
nity and nosocomial urinary tract infection (UTI). In the
UK, trimethoprim or nitrofurantoin are usually recom-
mended for empirical treatment of episodes of uncompli-
cated cystitis in the community [1], whilst parenteral
cephalosporins and aminoglycosides are reserved for
complicated infections or pyelonephritis. In North Amer-
ica a cut off point of 20% has been suggested as the level
of resistance at which an agent should no longer be used
empirically [2]. A UK study of the antimicrobial suscepti-
bility of bacterial pathogens causing UTI in 1999 – 2000
showed high levels of resistance to trimethoprim, amoxi-
cillin and oral cephalosporins [3] whilst a study of three
collections of E. coli strains obtained from patients in East
London in 1991, 1999 and 2004 showed rates of trimeth-
oprim resistance of over 30% [4]. The emergence of
strains producing extended spectrum β-lactamases
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threatens the empirical use of both cephalosporins and
ciprofloxacin [5] seriously limiting treatment regimens. In
order to determine current levels of resistance to antibiot-
ics commonly used locally for empirical treatment, we
reviewed susceptibility to ampicillin, amoxicillin/
clavaulanate, trimethoprim, nitrofurantoin, cefalexin,
gentamicin, ciprofloxacin and cefpodoxime amongst all
E. coli urinary isolates obtained in our laboratory over a 1
year period.
Methods
All E. coli isolates recovered from urine samples submitted
for microscopy, culture and sensitivity to the laboratories
of Barts and The London NHS Trust between 1st January
and 31st December 2005 were included. Samples originat-
ing from General practice, Accident and Emergency or
other primary care destinations were considered repre-
sentative of community isolates whilst samples originat-
ing from patients hospitalised for 48 hrs or more on
general or specialised wards were considered nosocomial.
Primary isolation of strains from urine specimens was per-
formed using chromogenic agar (Mast diagnostics,
Bootle, Merseyside) and bacterial counts quantified by
inoculation of 0.3 μl of urine onto cystine lactose electro-
lyte deficient (CLED) agar (Mast diagnostics). Sensitivity
testing was performed by the BSAC disc diffusion method
using ampicillin (25 μg), cefalexin (30 μg), gentamicin
(10 μg), ciprofloxacin (1 μg), nitrofurantoin (200 μg), tri-
methoprim (2.5 μg), amoxicillin/clavulanate (30 μg) and
cefpodoxime (10 μg) discs and isosensitest agar.
Multi-drug resistance was defined in this analysis as resist-
ance to three or more of the following antibiotics: cipro-
floxacin, cefpodoxime, amoxicillin/clavulanate and
gentamicin.
Differences in the prevalence of antibiotic resistance
between groups were analysed using the χ2 test. Strength
of association was assessed by calculation of odds ratios
with 95% confidence intervals.
Results
A total of 11,865 E. coli isolates were cultured from urine
samples over the study period, of these 10,521 (88.7%)
were considered community isolates while 1,344 (11.3%)
were of nosocomial origin. 10,166 (85.7%) were from
women and 1,656 (14.0%) from men (43 sex unknown).
1,227 (10.3%) were from children < 16 years of age.
The frequency of antimicrobial susceptibility of all iso-
lates to the eight antibiotics is shown in tables 1, 2, 3.
Nitrofurantoin was the most active agent (94% suscepti-
ble) followed by gentamicin (93.7%) and cefpodoxime
(92%). Ampicillin and trimethoprim were the least active
agents with 55% and 40% of isolates exhibiting resistance
respectively.
Isolates from men were significantly more resistant to all
eight agents than isolates from women (Table 1). In par-
ticular, resistance to cefpodoxime, gentamicin, cipro-
floxacin and cefalexin was observed more than twice as
frequently in isolates from men (odds ratios = 2.5). A sig-
nificant difference between paediatric and adult isolates
was seen for all agents except amoxicillin/clavulanate.
Resistance to cefalexin, ciprofloxacin, gentamicin, nitro-
furantoin and cefpodoxime was more common in adults
whilst ampicillin (OR 0.72) and trimethoprim (OR 0.76)
resistance was associated with paediatric strains (Table 2).
Nosocomial isolates were more resistant than community
isolates to all agents tested. The prevalence of gentamicin
(OR 4.93), ciprofloxacin (OR 4.74), and cefpodoxime
(OR 4.48) resistance exhibited the most marked differ-
ences (Table 3). Patterns of multi-drug resistance are
shown in table 4. Ampicillin resistance in combination
with trimethoprim resistance was more frequently
observed than resistance to the single agent alone, the
combination of ampicillin and trimethoprim resistance
was also seen in combination with amoxicillin/clavu-
Table 1: Frequency of antibiotic susceptibility in relation to sex
Antibiotic Female (n = 10157) Male (n = 1656) P OR (CI95%)
n n (%) Resistant n n (%) Resistant
Ampicillin 10153 5460 (53.8) 1652 1051 (63.6) ≤0.001 1.50 (1.35–1.67)
Amoxicillin/clavulanate 9178 1139 (12.4) 1491 310 (20.8) ≤0.001 1.85 (1.61–2.13)
Cefalexin 10139 892 (8.8) 1643 321 (19.5) ≤0.001 2.52 (2.19–2.90)
Ciprofloxacin 10137 1038 (10.2) 1649 374 (22.7) ≤0.001 2.57 (2.25–2.93)
Gentamicin 10149 525 (5.2) 1655 214 (12.9) ≤0.001 2.72 (2.30–3.22)
Nitrofurantoin 10134 551 (5.4) 1647 142 (8.6) ≤0.001 1.64 (1.35–1.99)
Trimethoprim 10138 3989 (39.3) 1652 748 (45.3) ≤0.001 1.28 (1.15–1.42)
Cefpodoxime 8512 525 (6.2) 1418 215 (15.2) ≤0.001 2.72 (2.29–3.22)Page 2 of 4
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nitrofurantoin was the most common multi-drug resistant
phenotype and was observed in 1.3% of isolates.
Discussion
In the UK most uncomplicated urinary tract infections are
treated in the community with short courses of empirical
antibiotics. This relies on susceptibility data from local
surveillance schemes as in many cases urine samples are
only sent for microbiological evaluation following treat-
ment failure, recurrent or relapsing infection. Although
the levels of resistance we observed amongst community
isolates may therefore overestimate the true rate of resist-
ance in the community, the high levels of resistance to
ampicillin and trimethoprim raise concerns over the use
of these agents. This was particularly evident amongst iso-
lates from children, which were more likely to exhibit
resistance to ampicillin and trimethoprim compared to
those from adults. Increased resistance to the other agents
in adults is likely to reflect their wider use both empiri-
cally and as second line therapies in relapsing, compli-
cated or nosocomial infection. The higher rates of
resistance to all agents observed in males are likely to
reflect the complicated nature of UTI in men [6]. Infection
in this group usually occurs in the setting of underlying
anatomical or functional abnormalities or following
instrumentation of the urinary tract and the use of pro-
phylactic antimicrobials. Data on resistance rates in E. coli
collected at another London teaching hospital from 1995
– 2000 reveal year on year increases in resistance to amox-
icillin, cefuroxime, gentamicin and ciprofloxacin [7].
Resistance to comparable agents in 2005 shows marked
elevations in resistance to gentamicin (6.3% v 3.2%) and
in particular ciprofloxacin (12% v 1.9%). Resistance to
cefpodoxime, which may signify ESBL production [8] was
seen in 7.4% of isolates overall, often in combination
with resistance to quinolones, aminoglycosides and tri-
methoprim. Although cefpodoxime resistance was more
typical of nosocomial isolates, significant resistance was
also observed in the community. These isolates most
likely represent CTX-M producing strains of E. coli which
have disseminated widely throughout Europe post 2000
[9] with those producing CTX-M-15 being most wide-
spread in the UK [10].
Conclusion
Nitrofurantoin remained the most active agent and as it
can be administered orally and is highly concentrated in
urine, it may therfore be the most appropriate agent for
empirical use in uncomplicated UTI. Empirical treatment
for nosocomial UTI or infection with multi-drug resistant
isolates remains challenging with many authorities rec-
ommending parenteral carbapenems (imipenem, ertap-
enem or meropenem) [11] especially where ESBL
Table 2: Frequency of antibiotic susceptibility in relation to age
Antibiotic < 16 years ≥ 16 years P OR (CI95%)
n n (%) Resistant n n (%) Resistant
Ampicillin 1225 763 (62.3) 10484 5694 (54.3) ≤0.001 0.72 (0.64–0.81)
Amoxicillin/clavulanate 1109 143 (12.9) 9480 1296 (13.7) NS 1.07 (0.89–1.29)
Cefalexin 1225 100 (8.2) 10462 1104 (10.6) ≤0.01 1.33 (1.07–1.64)
Ciprofloxacin 1224 72 (5.9) 10468 1334 (12.7) ≤0.001 2.34 (1.83–2.99)
Gentamicin 1226 44 (3.6) 10482 693 (6.6) ≤0.001 1.90 (1.39–2.59)
Nitrofurantoin 1224 46 (3.8) 10462 643 (6.1) ≤0.001 1.68 (1.24–2.28)
Trimethoprim 1223 566 (46.3) 10471 4129 (39.4) ≤0.001 0.76 (0.67–0.85)
Cefpodoxime 1064 43 (4.0) 8787 691 (7.9) ≤0.001 2.03 (1.48–2.78)
Table 3: Frequency of antibiotic susceptibility among community and nosocomial isolates
Antibiotic Community Nosocomial P OR (CI95%)
n n (%) Resistant n n (%) Resistant
Ampicillin 10509 5663 (53.9) 1339 870 (65.0) ≤0.001 1.59 (1.41–1.79)
Amoxicillin/clavulanate 9564 1145 (12.0) 1145 307 (26.8) ≤0.001 2.69 (2.33–3.11)
Cefalexin 10498 876 (8.3) 1327 340 (25.6) ≤0.001 3.78 (3.29–4.36)
Ciprofloxacin 10488 974 (9.3) 1341 441 (32.9) ≤0.001 4.79 (4.20–5.46)
Gentamicin 10505 482 (4.6) 1342 260 (19.4) ≤0.001 5.00 (4.24–5.88)
Nitrofurantoin 10492 556 (5.3) 1332 139 (10.4) ≤0.001 2.08 (1.71–2.53)
Trimethoprim 10492 4103 (39.1) 1341 649 (48.4) ≤0.001 1.46 (1.30–1.64)
Cefpodoxime 8868 504 (5.7) 1103 238 (21.6) ≤0.001 4.57 (3.85–5.41)Page 3 of 4
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producing isolates may be involved. The increasing rates
of resistance to uropathogenic E. coli isolates reported
worldwide [12,13] warrants evaluation of other treat-
ments such as fosfomycin [14] or possibly novel cepha-
losporin/inhibitor combinations [15].
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Table 4: Distribution of ten most frequently observed antibiotic 
resistance patterns.
Antibiotic n (%)
Susceptible 4290 36.13
AMP, TRI 2180 18.36
AMP 1835 15.46
TRI 691 5.82
AMP, AMC, TRI 292 2.46
AMP, AMC 265 2.23
AMP, CIP, TRI 241 2.03
AMP, AMC, LEX, CIP, GEN, TRI, CPD 164 1.38
AMP, AMC, LEX, CIP, TRI, CPD 98 0.83
AMP, NIT, TRI 95 0.80
Other 1722 14.50
Total 10151 100
AMP; ampicillin, TRI; trimethoprim, AMC; amoxicillin/clavulanate, CIP; 
ciprofloxacin, LEX; cefalexin, GEN; gentamicin, CPD; cefpodoxime, 
NIT; nitrofurantoinPage 4 of 4
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